Olympus Corporation (OCPNF) Stock Price & Analysis
Olympus Corporation (OCPNF) — price $12.13 (0.00%), as of the Oct 2, 2026 trading session; market cap $13.4B. Expected results Nov 6, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Olympus Corporation · OCPNF · Healthcare · Medical - Devices
Established in Tokyo, Japan, in 1919, Olympus Corporation is a global leader in the manufacturing and distribution of advanced precision machinery and scientific instruments.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $12.13 | |
| Change on the day | 0.00% | |
| 52-week range | $8.00 – $14.00 | |
| Market capitalisation | $13.4B | |
| Price / earnings (trailing) | 27.52 | |
| Shares traded on the day | 10.0K | |
| Beta (volatility vs the S&P 500) | 0.2 | |
| Dividends per share (last 12 months) | $0.38 | |
| Dividend yield (last 12 months) | 3.13% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Chronological order, not a duration scale. The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Olympus (OCPNF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 24, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the OCPNF film — every key number, told as a short cinematic story
~2 min · open the film
What is Olympus (OCPNF), and what does it report?
Short answer · as of
Established in Tokyo, Japan, in 1919, Olympus Corporation is a global leader in the manufacturing and distribution of advanced precision machinery and scientific instruments. Healthcare / Medical Devices Headquarters: 2951, Ishikawa-machi, Hachioji, TY, 192-8507, JP. It employs 28,138 people and is led by Robert White. In Q1 FY2027 it reported revenue of $1.51B and net income of $120M. The market values it at $13.4B.
What do the latest results show for Olympus (OCPNF)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $1.51B. Against analyst estimates the company has EPS beat 3 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.48B Aug 7, 2026
- Latest report · revenue estimate
- $1.39B Aug 7, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 7, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 7, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 7, 2026 | $1.48B | $1.39B | $0.1092 | $0.0531 |
| May 12, 2026 | $1.86B | $1.78B | $0.1414 | $0.0482 |
| Feb 13, 2026 | $1.67B | $1.66B | $0.0821 | $0.1471 |
| Nov 7, 2025 | $1.68B | $1.60B | $0.1219 | $0.1371 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $1.51B | $120M | $0.11 (diluted) |
| Q4 FY2026 | $1.88B | $158M | $0.14 (diluted) |
| Q3 FY2026 | $1.66B | $90M | $0.08 (diluted) |
| Q2 FY2026 | $1.57B | $128M | $0.11 (diluted) |
What are the financial strengths and risks for Olympus (OCPNF)?
Short answer
The distress and quality screens read Altman Z 3.18 · Piotroski F 7. Trailing ratios: ROE 10.2% · ROA 5.1% · current ratio 1.36 · earnings yield 3.7% · free-cash-flow yield 3.3%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Rich valuation — a P/E of 27.52 runs well above the Healthcare sector’s ~21.10x, leaving little room for a miss.
What should you watch next at Olympus (OCPNF)?
Short answer · as of
The next earnings report is expected on Nov 6, 2026.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is Olympus scored?
Research dated 2026-09-13.
Olympus differs from a disposable-focused device supplier because its model joins complex endoscopy platforms with procedure tools, reprocessors, repair, maintenance, and system integration. A system placement can support later clinical use and service activity, so the commercial relationship can persist beyond the original equipment shipment.
It also differs from a narrowly clinical manufacturer through microscopes and industrial inspection technologies. Investors comparing Olympus with medical-device peers are therefore comparing a mixed installed-base and precision-instrument model, not merely a stream of surgical product sales.
| Company | Price | Market value | Score |
|---|---|---|---|
| $43.93 Oct 2, 2026 | $15.2B | — Model unavailable | |
| $8.80 Oct 2, 2026 | $15.0B | — Model unavailable | |
| $26.01 Oct 2, 2026 | $15.3B | — Model unavailable | |
| $85.95 Oct 2, 2026 | $14.9B | — Model unavailable | |
| $1.11 Oct 2, 2026 | $12.7B | — Model unavailable | |
| $317.55 Oct 2, 2026 | $12.5B | — 5-pillar · not comparable | |
| $26.42 Oct 2, 2026 | $11.1B | — 5-pillar · not comparable | |
| $88.29 Oct 2, 2026 | $17.1B | — 5-pillar · not comparable | |
| $143.74 Oct 2, 2026 | $10.3B | — 5-pillar · not comparable | |
| $75.60 Oct 2, 2026 | $10.2B | — 5-pillar · not comparable | |
| $369.14 Oct 2, 2026 | $9.94B | — 5-pillar · not comparable | |
| $163.75 Oct 2, 2026 | $9.66B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What has been published about Olympus (OCPNF)?
OCPNF Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why do Olympus endoscope repair services matter to the business model?
Repair and maintenance keep endoscopy systems in use and extend Olympus's relationship with the installed base beyond the equipment sale. That service connection can accompany demand for procedure tools, reprocessors, and system integration.
Does Olympus rely solely on hospital endoscopy systems?
Hospital endoscopy is only part of the product set. Olympus also sells therapeutic devices, microscopes, industrial videoscopes, testing equipment, analyzers, biomedical materials, orthopedic equipment, and related services.
What is the OCPNF stock price today?
The last price recorded on this page for Olympus Corporation (OCPNF) is $12.13, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does OCPNF pay a dividend?
Yes. Olympus Corporation (OCPNF) shows a trailing 12-month dividend yield of 3.13%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (41 figures)
The 41 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 32 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $12.13 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T22:24:21.267Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $13.4B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T22:24:17.451Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 6, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Established in Tokyo, Japan, in 1919, Olympus Corporation is a global leader in the manufacturing and distribution of advanced precision machinery and scientific instruments. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 27.52 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 10.0K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.2 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Devices | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | 2951, Ishikawa-machi, Hachioji, TY, 192-8507, JP | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 28,138 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Robert White | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q1 FY2027 | $1.51B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q1 FY2027 | $120M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-07.revenue_actual | Revenue · reported — report date 2026-08-07 | $1.48B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-07.revenue_estimated | Revenue · estimate — report date 2026-08-07 | $1.39B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-07.eps_actual | EPS · reported — report date 2026-08-07 | $0.1092 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-07.eps_estimated | EPS · estimate — report date 2026-08-07 | $0.0531 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_actual | Revenue · reported — report date 2026-05-12 | $1.86B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_estimated | Revenue · estimate — report date 2026-05-12 | $1.78B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_actual | EPS · reported — report date 2026-05-12 | $0.1414 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_estimated | EPS · estimate — report date 2026-05-12 | $0.0482 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.revenue_actual | Revenue · reported — report date 2026-02-13 | $1.67B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.revenue_estimated | Revenue · estimate — report date 2026-02-13 | $1.66B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.eps_actual | EPS · reported — report date 2026-02-13 | $0.0821 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.eps_estimated | EPS · estimate — report date 2026-02-13 | $0.1471 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.revenue_actual | Revenue · reported — report date 2025-11-07 | $1.68B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.revenue_estimated | Revenue · estimate — report date 2025-11-07 | $1.60B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.eps_actual | EPS · reported — report date 2025-11-07 | $0.1219 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.eps_estimated | EPS · estimate — report date 2025-11-07 | $0.1371 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2027 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $8.00 – $14.00 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 3.18 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 10.2% · ROA 5.1% · current ratio 1.36 · earnings yield 3.7% · free-cash-flow yield 3.3% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.38 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 3.13% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-07.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.48B) with the recorded estimate ($1.39B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-07.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.1092) with the recorded estimate ($0.0531) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-07. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-07.revenue_actual,earn.history.depth.2026-08-07.revenue_estimated,earn.history.depth.2026-08-07.revenue_actual.comparison,earn.history.depth.2026-08-07.eps_actual.comparison,earn.history.depth.2026-08-07.eps_actual,earn.history.depth.2026-08-07.eps_estimated,earn.history.depth.2026-05-12.revenue_actual,earn.history.depth.2026-05-12.revenue_estimated,earn.history.depth.2026-05-12.eps_actual,earn.history.depth.2026-05-12.eps_estimated,earn.history.depth.2026-02-13.revenue_actual,earn.history.depth.2026-02-13.revenue_estimated,earn.history.depth.2026-02-13.eps_actual,earn.history.depth.2026-02-13.eps_estimated,earn.history.depth.2025-11-07.revenue_actual,earn.history.depth.2025-11-07.revenue_estimated,earn.history.depth.2025-11-07.eps_actual,earn.history.depth.2025-11-07.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Established in Tokyo, Japan, in 1919, Olympus Corporation is a global leader in the manufacturing and distribution of advanced precision machinery and scientific instruments. The company structures its diverse operations into four main segments. Its Endoscopic Solutions division provides sophisticated endoscopic tools for gastrointestinal and surgical procedures, along with complete endoscopy systems and crucial repair services. The Therapeutic Solutions segment delivers specialized medical devices for urology, gynecology, and otolaryngology (ear, nose, and throat), alongside endo-therapy and energy-based devices, and single-use surgical instruments. Under its Scientific Solutions umbrella, Olympus supplies an array of biological and industrial microscopes, industrial inspection equipment including endoscopes and videoscopes, non-destructive testing apparatus, and X-ray fluorescence (XRF) analyzers. The "Others" category encompasses biomedical materials and orthopedic equipment. Furthermore, Olympus's extensive offerings include additional medical technologies such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, supported by system integration and comprehensive maintenance and service programs. The company, which was originally known as Olympus Optical Co., Ltd., officially rebranded as Olympus Corporation in October 2003. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Devices | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.